Opus Genetics, Inc. (IRD)
NASDAQ: IRD · Real-Time Price · USD
0.9500
+0.0032 (0.34%)
At close: May 12, 2025, 4:00 PM
0.9212
-0.0288 (-3.03%)
After-hours: May 12, 2025, 6:49 PM EDT
Opus Genetics Stock Forecast
Stock Price Forecast
According to 2 professional analysts, the 12-month price target for Opus Genetics stock ranges from a low of $6.00 to a high of $8.00. The average price target of $7.00 forecasts a 636.84% increase in the stock price over the next year.
Price Target: $7.00 (+636.84%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Apr 11, 2025.
Analyst Ratings
The average analyst rating for Opus Genetics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Craig-Hallum | Craig-Hallum | Strong Buy Initiates $6 | Strong Buy | Initiates | $6 | +531.58% | Apr 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +742.11% | Apr 1, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +742.11% | Feb 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +742.11% | Dec 12, 2024 |
Financial Forecast
Revenue This Year
13.41M
from 10.99M
Increased by 22.00%
Revenue Next Year
26.94M
from 13.41M
Increased by 100.89%
EPS This Year
-0.91
from -2.15
EPS Next Year
-0.52
from -0.91
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 18.2M | 31.5M | 41.3M | ||
| Avg | 13.4M | 26.9M | 24.4M | ||
| Low | 9.8M | 21.7M | 9.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 65.3% | 134.9% | 53.2% | ||
| Avg | 22.0% | 100.9% | -9.3% | ||
| Low | -10.8% | 61.7% | -63.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.84 | -0.42 | -0.55 | ||
| Avg | -0.91 | -0.52 | -0.60 | ||
| Low | -1.07 | -0.72 | -0.71 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.